Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 and\<45 years old.~2. Female patients with documented diagnosis of POF: \<40 years old, at least 4 months of amenorrhea not due to pregnancy, two FSH levels above 40 IU/L, at least one month apart.~3. Not in other trial within 3 months prior to the start of this trial.~4. Willing to participate in this trial and to give informed consent/assent before any procedures are performed in this trial.~Exclusion Criteria:~1. History of, or evidence of current malignancy within the past 5 years.~2. Severe functional impairment of vital organs.~3. Abnormal karyotype.~4. Coagulation disorders.~5. Severe pelvic adhesions.~6. Uncontrolled acute or chronic gynecologic inflammation.~7. Congenital adrenal cortical hyperplasia.~8. Cushing's syndrome.~9. Thyroid dysfunction.~10. Pituitary adenoma.~11. Pituitary amenorrhea or Hypothalamic amenorrhea.~12. Thrombophlebitis, venous thrombosis or artery thrombosis.~13. History of Oophorocystectomy.~14. Currently pregnant or breast-feeding.~15. Currently receiving other treatment that might affect the efficacy and safety of stem cells.~16. History of severe drug allergy.~17. Active infection detected by chest X-ray/CT.~18. HIV, TPAb positive.~19. Mental illness.~20. Currently participating in any other clinical trial that uses interventional drugs or examinations.~21. Patients that are deemed, by the investigator, inappropriate to participate in this trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- hAECs transplantation (Type: EXPERIMENTAL): To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients

Based on this trial design, predict the completion outcome and termination type (if applicable).